News | March 13, 2024
Nirma acquires majority stake in Glenmark Life Sciences
Completes acquisition of 75% of share capital from Glenmark Pharmaceuticals
Completes acquisition of 75% of share capital from Glenmark Pharmaceuticals
he lower sales in the current quarter are mainly on account of a one?time impact on the company’s India business
Developed by Pfizer, Abrocitinib has received marketing authorization from the Central Drugs Standard Control Organization (CDSCO) in India
This alliance brings together drug innovation capabilities of Glenmark and Ichnos to develop cutting-edge therapies for the treatment of hematological malignancies and solid tumors
Glenmark will be responsible for further developing, registering, and commercializing Envafolimab in India, Asia Pacific, Middle East and Africa, Russia, CIS, and Latin America
Glenmark Life Sciences has reported total income of Rs. 574.49 crores during the period ended December 31, 2023
Glenmark Life Sciences will manufacture API in the therapeutic area of urinary anti-spasmodic, to supply to the global innovator
Liraglutide belongs to the class of glucagon like peptide 1 receptor agonist (GLP?1 RA) drugs
European operations' revenue grew 58.4% to Rs 599.7 crore
Glenmark's Zita portfolio of medicines have been benefiting around 1.75 million Type 2 diabetic patients annually
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)